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STEALTH CELEBRITY TESTIMONIALS OF
PRESCRIPTION DRUGS: PLACING THE
CONSUMER IN HARM'S WAY AND HOW THE
FDA HAS DROPPED THE BALL
I. INTRODUCTION AND OVERVIEW
This is the age of "mass-media spam."' As TIVO2 and other
technological advances have empowered consumers-making message
avoidance easier-the advertising industry's response has been to increase
output.3  For some advertisers, the solution to breaking through to
consumers who sidestep traditional advertising has been to disguise their
sales message in editorial or news content.4  Depending on the manner
employed, these stealth advertisements pose unique dangers to the general
public. This is the case with stealth prescription drug advertising.
Historically, pharmaceutical companies directed their advertising
solely towards physicians.5 However, with the approval of the Food and
Drug Administration (FDA), 6 the prescription drug industry has begun
1. Herbert Jack Rotfield, Understanding Advertising Clutter and the Real Solution to
Declining Audience Attention to Mass Media Commercial Messages, 23 J. OF CONSUMER MKTG.
180, 180 (2006).
2. See TIVO-Wikipedia, The Free Encyclopedia, http://en.wikipedia.org/wiki/TIVO (last
visited Feb. 7, 2008) (explaining that TIVO is the brand-name of a popular digital video
recording device that allows its users to transform television signals into captured digital files, to
play back these files at their convenience, and to manipulate these files such that advertisements
are bypassed entirely).
3. Rotfield, supra note 1, at 181.
4. Id.
5. See generally Alison J. Huang, The Rise of Direct-to-Consumer Advertising of
Prescription Drugs in the United States, 284 MED. STUDENT J. AM. MED. ASS'N 2240 (2000).
6. The FDA is the agency tasked with the authority of monitoring pharmaceutical
advertisements in the United States. The FDA generally cannot require the prescreening of
prescription drug advertisements. Rather, the FDA reviews materials after their dissemination to
the public, and then makes a decision as to whether enforcement is appropriate. See FDA
Regulates Prescription Drug Promotion: Hearing Before the S. Comm. On Aging, 108th Cong.
36 (2003) [hereinafter FDA Regulates Prescription Drug Promotion] (statement of Janet
Woodcock, Director Center for Drug Evaluation and Research, Food and Drug Administration).
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advertising directly to consumers.7  In doing so, prescription drug
companies have utilized celebrity testimonials to promote their products.8
One means of employing celebrity testimonials is to have celebrities
promote prescription drugs in formats that are not clearly commercial in
nature, such as television talk shows.9  Particularly concerning are
testimonials where the celebrity has failed to disclose the side effects of the
promoted drug, as well as the financial consideration the celebrity has
received for the promotion.' 0
These stealth testimonials exploit the unique influence celebrities
have over consumers in order to promote products that, if misused, may
have life threatening implications. Through celebrity stealth testimonials,
the prescription drug industry flouts FDA advertising regulations requiring
disclosures designed to ensure consumer safety."1 Yet, the FDA has failed
to regulate this form of Direct-to-Consumer (DTC) advertising.1 2  This
Article focuses on the need for immediate FDA regulation of stealth
celebrity testimonials of prescription drugs.
Part II of this Article explores the development of pharmaceutical
advertising and the dangers associated with DTC advertising of
prescription drugs. Part III examines the statutory and regulatory
framework governing advertisements of prescription drugs. Part IV asserts
that the FDA must begin to regulate celebrity stealth testimonials of
prescription drugs. Part V provides alternatives for how the FDA might
regulate celebrity testimonials of prescription drugs. Part VI concludes that
in the absence of governmental action, consumer safety remains in
jeopardy.
7. Id.
8. See CBSNews.com, Stars Profit from Covert Pitches Unbeknownst to Viewers, CBS
NEWS, Aug. 29, 2002,
http://www.cbsnews.com/stories/2002/08/29/entertainment/main520196.shtml (last visited Feb.
7, 2008).
9. See id.; see also Melody Petersen, Heartfelt Advice Hefty Fees, N.Y. TIMES, Aug. 11,
2002, at 1 (concerning Kathleen Turner's appearance on Good Morning America for Wyeth).
10. Petersen, supra note 9.
11. See 21 C.F.R § 202. l(e)(1) (2006) ("All advertisements for any prescription
drug... shall present a true statement of information in brief summary relating to side effects,
contraindications ... ").
12. See Warning Letters and Untitled Letters to Pharmaceutical Companies 2007-1997,
http://www.fda.gov/cder/wam/wam2007.htm (last visited Feb. 8, 2008).
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II. BACKGROUND AND HISTORICAL DEVELOPMENT OF THE ISSUE
A. The Evolution of Prescription Drug Advertising
Pharmaceutical advertising aimed directly at the consumer is a
relatively new phenomenon.' 3  Prescription drug manufacturers have
historically been reluctant to advertise in this manner. 14  Legislation
intended to protect the public combined with the unique paternalistic
relationship that physicians share with their patients had largely kept them
away from such advertising. 15 Instead, the traditional focus had been on
advertising solely to physicians. 16
In the past, physicians generally played the role of sole decision
maker in determining prescription medications for their patients, leaving
little economic incentive for drug companies to advertise directly to
consumers. 17 In fact, it was not until the 1980s that prescription drugs were
first marketed directly to consumers. 
18
The initial Direct-to-Consumer (DTC) prescription drug
advertisements were the result of consumers taking a larger role in the
medical decision making process and a changed regulatory climate
empowering them to do so. 19 Boots Pharmaceuticals issued the first
American prescription drug print advertisement directed towards
consumers in 1981.20 In the same year, the pharmaceutical company
Merck, Sharp, & Dohme released the second print DTC prescription drug
advertisement-for a pneumonia vaccine.21 Facing a unique method of
advertising that was gaining favor among prescription drug manufacturers,
the Food and Drug Administration (FDA) requested that the
pharmaceutical industry temporarily abstain from producing DTC
13. Huang, supra note 5 ("Prior to the early 1980s, pharmaceutical companies promoted
their prescription products exclusively to physicians, who were expected to act as 'learned
intermediaries' interpreting drug information forthe general public.").
14. Id.
15. Id.
16. Francis B. Palumbo & C. Daniel Mullins, The Development of Direct to Consumer
Advertising Regulation, 57 FOOD & DRUG L.J. 423, 424 (2002).
17. Huang, supra note 5.
18. FDA Regulates Prescription Drug Promotion, supra note 6, at 34 (statement of Janet
Woodcock, Director Center for Drug Evaluation and Research, Food and Drug Administration).
19. Huang, supra note 5.
20. Wayne L. Pines, A History and Perspective on Direct-to-Consumer Promotion, 54
FOOD & DRUG L.J. 489, 491 (1999).
21. Id.
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advertisements.22 During this time, the FDA assessed whether existing
advertisement regulations were able to safeguard consumer health in the
face of DTC advertising, and conducted a cost-benefit analysis to decide if
DTC advertisements should be allowed to continue.23
During the moratorium, the FDA studied the effects of DTC
advertisements.24  In 1985, the FDA settled its position on the
dissemination of DTC advertising for prescription drugs.2 5 It concluded
that the benefits of DTC advertising were not outweighed by any associated
harm.26 Additionally, the FDA determined that existing advertising
regulations were sufficient to protect consumers, and lifted the DTC
advertising moratorium.27
The moratorium's removal set the stage for the rapid adoption of
DTC advertising by the pharmaceutical industry. To understand the
popularity of this form of advertising in the industry, one need only look to
the exponential increase in total annual expenditures on such advertising
over the past decade. 28 Total annual spending on DTC advertising grew
from $985 million in 1996 to over $4.2 billion in 2005, representing a
330% increase.29
The increased spending on DTC advertising stems from the success it
has generated for the pharmaceutical industry.30 The industry receives
$4.20 for every dollar it spends on DTC advertising.31 DTC advertising is
so profitable because of its "pull effect" on consumers.32 Evidence from
consumer surveys indicates that DTC advertising encourages consumers to
22. FDA Regulates Prescription Drug Promotion, supra note 6, at 34 (statement of Janet
Woodcock, Director Center for Drug Evaluation and Research, Food and Drug Administration).
23. Id. at 37.
24. Jane E. Henney, Challenges in Regulating Direct-to-Consumer Advertising, 284 MED.
STUDENT J. AM. MED. ASS'N 2242 (2000).
25. Id.
26. JOHN E. CALFEE, PUBLIC POLICY ISSUES IN DIRECT-TO-CONSUMER ADVERTISING OF
PRESCRIPTION DRUGS 9 (2002),
http://www.fda.gov/ohrms/dockets/dailys/O2/SepO2/092302/02N-0209_emc-000 183-01 .pdf.
27. See FDA, DIRECT TO CONSUMER ADVERTISING OF PRESCRIPTION DRUGS;
WITHDRAWAL OF MORATORIUM, 50 Fed. Reg. 36,677 (Sept. 9, 1985).
28. See Julie M. Donahue et al., A Decade of Direct to Consumer Advertising of
Prescription Drugs, 357 NEW ENG. J. MED. 673 (2007).
29. Id. at 676.
30. See MEREDITH B. ROSENTHAL ET AL., HENRY J. KAISER FAMILY FOUND., DEMAND
EFFECTS OF RECENT CHANGES IN PRESCRIPTION DRUG PROMOTION 16 (2003),
http://www.kff.org/rxdrugs/upload/Demand-Effects-of-Recent-Changes-in-Precription-Drug-
Promotion-Report.pdf.
31. Id.
32. See generally U.S. GEN. ACCOUNTING OFFICE, PRESCRIPTION DRUGS: FDA
OVERSIGHT OF DIRECT-TO-CONSUMER ADVERTISING HAS LIMITATIONS (2002).
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request prescriptions for specific drugs from their physicians who then
provide the requested prescription. 3  The surveys asked whether
consumers had seen an advertisement for a particular prescription drug and
whether seeing that advertisement resulted in the consumer discussing with
their physician the particular drug mentioned.34 The respondents answered
in the affirmative between sixty-five and eighty-five percent of the time. 35
When compared to traditional advertising, the benefits of DTC
advertising are clear. Prescription drugs promoted directly towards
consumers quickly become bestselling drugs, and sales of DTC-advertised
drugs increased faster than sales for drugs not advertised in such a
manner. 36 For example, in 2000, twenty-two of the fifty drugs with the
highest DTC spending were among the top fifty in sales.37
Today, when an individual turns on the television or reads a
newspaper or magazine, their exposure to an onslaught of prescription drug
advertisements is near certain. 38 The FDA and those in the health industry
have characterized the explosion of DTC drug advertising as having an
overall benefit to the consumer.39 While such advertisements can provide
consumers with useful information and improve their interactions with
physicians-creating a better informed consumer-they can also expose
the public to significant dangers.40 These dangers can heighten when
celebrities are associated with the advertising.41
How best to protect the public from the dangers associated with DTC
prescription drug advertising is a struggle for the FDA and Congress.4 2
Recent Congressional action aims to improve the regulation of DTC
advertising.4 3 However, the combination of Congress' failure to address
33. See id. at 11.
34. See id. at 16.
35. See id.
36. See id. at 3.
37. See id.
38. See generally CALFEE, supra note 26.
39. See generally id.
40. Id. at 31.
41. See generally Direct-to-Consumer Prescription Drug Advertising: Hearing Before U.S.
Food and Drug Administration, 109-10 (Nov. 2, 2005) (statement of Gary Ruskin, Executive
Director of Commercial Alert).
42. See generally Arlene Weintraub, The Drug Advertising Debate, BUSINESSWEEK
ONLINE, July 16, 2007,
http://www.businessweek.com/technology/content/jul2007/tc200707l 5016528.htm?chan--top+n
ews.top+news+indexbusinessweek+exclusives (discussing recent Congressional attempts to
limit drug marketing).
43. See Memorandum from Reed Smith LLP to Healthcare Clients (Oct. 24, 2007),
available at
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the dangers presented by stealth celebrity testimonials of prescription drugs
and the FDA's historical leniency towards regulating such advertising
continues to leave consumers in harm's way.
B. The Dangers Associated with DTC Advertising of Prescription Drugs
DTC advertising has been successful because it encourages
consumers to request specific brand-name drugs from their physicians, but
there are certain inherent dangers associated with this.4 The fundamental
flaw is the inability to provide consumers "complete, meaningful, and
useful information. 45  A significant conflict of interest exists with a
pharmaceutical company presenting complete and unbiased information
about its products, because, while prescription drug companies obviously
have a financial interest in seeing their products succeed, this interest can
be at odds with the full disclosure of a particular drug's dangers.
A recent DTC advertising campaign promoting new treatments for
HIV/AIDS illustrates this concern. 46 The advertisements-heavily laden
with visual imagery-created what critics said were unrealistic
expectations of treatment for patients and those at risk.47 Supporting the
criticism is a San Francisco survey which found that men who had
frequently seen the advertisements were more likely to engage in unsafe
sex.
48
Another concern about DTC advertising is the impact that it has on
the doctor-patient relationship.49 Critics argue that DTC advertising
encourages consumers to pressure health professionals to prescribe
particular medications that are often less effective and more expensive than
what they would normally prescribe. 50 A study conducted by the Journal
http://www.reedsmith.coml db/ documents/Food-and-Drug-LawClientMemoI 026.pdf.
(discussing the Food and Drug Act Amendments of 2007, which increased fees charged to
prescription drug companies in an effort to increase resources for review of television drug
advertising, and gave the FDA greater authority to pre-review advertisements).
44. See Direct-to-Consumer Prescription Drug Advertising, supra note 41, at 102-14
(statement of Gary Ruskin, Executive Director of Commercial Alert).
45. Id. at 102-03 (quoting Allen S. Cushion, Senior Vice President for Public Affairs,
Scheering Plough).
46. HEALTH ACTION INTERNATIONAL, DIRECT-TO-CONSUMER PRESCRIPTION DRUG
ADVERTISING: THE EUROPEAN COMMISSION'S PROPOSAL FOR LEGISLATIVE CHANGE 6 (2001),
available at http://www.haiweb.org/campaign/DTCA/BMintzes-en.pdf.
47. Id.
48. Id.
49. See MARK WAMSLEY, MEDIA EDUC. FOUND., A SoFr SELL FOR HARD DRUGS 2,
http://www.mediaed.org/news/articles/SoftSellHardDrugs (last visited Feb. 23, 2008).
50. See Impact of Direct-to-Consumer Drug Advertising on Seniors' Health and Health
Care Costs: Hearing Before the S. Spec. Comm. on Aging, 109th Cong. 88 (2005) [hereinafter
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of American Medicine analyzed the impact of an advertisement campaign
for a depression related drug treatment on sales of that drug.5' It found that
only ten percent of patients who had not made a specific request for an
advertised drug received a prescription for that drug, while fifty-five
percent of patients who specifically requested the drug received a
prescription for it.52 Further illustrating the impact of DTC advertising on
the doctor-patient relationship is a recent FDA survey of 500 physicians.53
Questioned about the problems DTC advertising creates for their practices,
the majority of the physicians responded that DTC advertising confuses
patients about the relative risks and benefits of advertised drugs and leads
to patients unnecessarily requesting prescriptions.54 The result is that
physicians are put in a position where they have to dissuade patients from
taking drugs that are wrong for the patient's particular ailments, but that
advertising has led patients to believe are right for them.
Celebrity advertisements amplify the above-mentioned dangers as
they hold a greater influence over the general public than traditional non-
celebrity advertisements. Thus, significant potential dangers exist when
drug companies use celebrities to advertise their drug products. 55  Of
particular concern are several advertising incidents where celebrities have
not disclosed that they are being compensated by drug manufacturers, or
have failed to make material disclosures about the side effects of the drug
they are promoting.56
C. The Celebrity Component
1. Big Pharma's Exploitation of Celebrity Star Power
Celebrities certainly have power and influence over the average
Impact of Direct-to-Consumer Drug Advertising] (statement of Peter Lurie, Deputy Director of
Public Citizens Health Research Group); WAMSLEY, supra note 49, at 2.
51. Impact of Direct-to-Consumer Drug Advertising, supra note 50, at 100 (statement of
Richard L. Kravitz, M.D., MSPH, Director, Center for Health Services Research in Primary Care,
University of California, Davis Medical Center).
52. Id.
53. See Kathryn J. Aikin, et al., Direct-to-Consumer Advertising of Prescription Drugs:
Physician Survey Preliminary Results,. Jan. 23, 2003,
http://www.fda.gov/cder/ddmac/globalsunmit2003 (follow link "click here to start
presentation").
54. Id.
55. Ray Moynihan, The Intangible Magic of Celebrity Marketing, 1 PUB. LIBR. SCI. MED.
102, 104 (2004).
56. Id.
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American, as evidenced by our seemingly endless fascination with them.57
Pharmaceutical companies, recognizing this power, are employing popular
celebrities to attract attention to their latest drugs.58  Examples include
professional athlete Ricky Williams' contract with pharmaceutical
company GSK to sell antidepressants, and politician Bob Dole's infamous
campaign for pharmaceutical company Pfizer's erectile dysfunction drug
Viagra.59  The tactic of employing celebrity advertising has been so
effective that firms exist solely to match celebrities with drug companies.60
As pharmaceutical companies continue to exploit celebrity star
power, the danger is that they may do so in a surreptitious or indirect
manner and that they may manipulate consumers by taking advantage of
the unique influence celebrities possess over the general public. Due to the
potential risks associated with the consumption of prescription drugs,
stealth celebrity testimonials of a pharmaceutical product can pose a
significant danger to the general public.
2. A New Tactic to Assault Consumers: Celebrity Stealth Marketing of
Prescription Drugs
The increasing clutter and fragmentation of the media and the
development of new technologies such as Digital Video Recording (DVR)
devices that empower the consumer to bypass television advertisements
impair the effectiveness of traditional forms of advertising. 6' The problem
for advertisers is the consumer's desire to avoid the "cacophony of
marketing messages aimed constantly toward the consuming public. 62 As
wary and cynical viewers are bombarded with an increasing number of
advertisements, some marketers have turned to more subtle methods of
communicating their message.63  This subset of marketing, where the
consumer is unaware that they are being marketed to is often referred to as
57. See, e.g., Perez Hilton, PerezHilton.com: Celebrity Juice, Not from Concentrate,
http://perezhilton.com (last visited Feb. 23, 2008); PageSix.com, http://www.pagesix.com (last
visited Feb. 23, 2008).
58. Moynihan, supra note 55, at 102-03.
59. Id. at 103.
60. Diedtra Henderson, Rise of Celebrity Testimonials Spurs FDA Scrutiny, BOSTON
GLOBE, Oct. 30, 2005, at Al.
61. Andrew M. Kaikati & Jack G. Kaikati, Stealth Marketing: How to Reach Consumers
Surreptitiously, 46 CAL. MGMT. REV. 6, 8 (2004).
62. Namita Bhatnagar, et al., Embedding Brands Within Media Content: The Impact of
Message, Media, and Consumer Characteristics on Placement Efficacy, in THE PSYCHOLOGY OF
ENTERTAINMENT MEDIA: BLURRING THE LINES BETWEEN ENTERTAINMENT AND PERSUASION
99 (L.J. Shrum ed., 2004) (2003).
63. Id.
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"stealth marketing., 64
Stealth marketing may occur in two forms.65 The first is conventional
payola marketing, where the sponsor purchases audience exposure as a
66form of advertising. The second is embedded marketing, which occurs
when promotional messages are embedded into editorial content.
67
Embedded marketing techniques can be traced to practices originally
developed for publicity purposes. 68 Such publicity practices generally
involve unpaid acts designed to attract public interest, as opposed to more
traditional advertising, which involves the paid dissemination of
messages.69 Stealth marketing has the effect of blurring the unpaid
"embedded marketing" with the "payola marketing., 70 In the context of
prescription drugs, stealth marketing has taken the form of celebrities
making stealth testimonials of specific drugs.71
Large pharmaceutical companies hire celebrities to appear on talk
shows discussing various diseases and promote specific drugs during a
casual chat with the host.72 A cause for concern arises when celebrities fail
to mention their financial ties to the pharmaceutical company sponsoring
them or fail to make any disclosures in regards to the side effects of the
drugs they are promoting.73 Critics have characterized such stealth
testimonials as essentially a commercial "masquerading as an interview."
74
Several noteworthy examples of stealth celebrity testimonials exist.
In 2002, Lauren Bacall, a prominent actress, appeared on NBC's Today
Show, and discussed a friend who had lost their sight from macular
degeneration.75 Bacall then encouraged members of the audience to see
their doctors for macular degeneration testing and proceeded to mention the
64. See generally Undercover Marketing-Wikipedia, The Free Encyclopedia,
http://en.wikipedia.org/wiki/Stealth-marketing (last visited Feb. 7, 2008).
65. See generally FCC Payola Rules,
http://www.fcc.gov/cgb/consumerfacts/PayolaRules.html (last visited Feb. 7, 2008).
66. See generally id.; Rotfield, supra note 1.
67. Rotfield, supra note 1, at 181.
68. See Anne R. Owen & James A. Karrh, Video News Releases: Effects on Viewer Recall
and Attitudes, 22 PUB. REL. REv. 369, 371-72 (1996).
69. See Bookpros.com, Publicity vs. Marketing,
http://www.bookpros.com/bp2006/divpuz/publicityys-marketing.php (last visited Feb. 7, 2008)
(distinguishing publicity and marketing).
70. Kaikati & Kaikati, supra note 61, at 12.
71. Id.
72. Id.
73. Id.
74. Id.
75. Petersen, supra note 9.
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drug Visudyne, a new treatment for the disease.76 What Bacall failed to
mention was that Novartis, the manufacturer of Visudyne, compensated her
for her time on the show.
77
Another incident involves an interview with Kathleen Turner, a
popular actress, on ABC's Good Morning America. 8 Turner appeared on
the show to discuss her rheumatoid arthritis. 79 During the interview, she
referred viewers to a website sponsored by pharmaceutical company
Wyeth, saying that new medications were "'extraordinarily effective' and
did not have any side effects., 80 Wyeth is not only the co-manufacturer of
Enbrel, an anti-arthritis drug, but also maintains the promoted website.8s
Turner, too, failed to mention that the manufacturers compensated her for
her public appearances on behalf of Enbrel. s2
A final example comes from CBS's The Montel Williams Show.
Williams, the show's host, has multiple schlerosis and featured the disease
on one of his shows. 83 During the show, Williams mentioned he takes
Copaxone, saying it is what has "kept [him] running." 84 Williams failed to
discuss both the drug's possible side effects and his financial ties to Teva
Pharmaceuticals, the manufacturer of Copaxone. 5
The dangers associated with DTC advertising are magnified when a
stealth celebrity testimonial occurs. The pharmaceutical company, relying
on a celebrity's unique influence over the public, manipulates the consumer
in a manner in which they are unaware. This is inherently dangerous in the
realm of prescription drugs; failing to fully inform the public can have
deadly effects.86
The events surrounding the rise and fall of pharmaceutical company
Merck's pain medication, Vioxx, illustrate the dangers of failing to inform
the public about the side effects of a prescription drug.87 Clinical trials and
studies conducted by Merck revealed that a potential side effect to Vioxx
76. Id.
77. Id.
78. Id.
79. Id.
80. Id.
81. Petersen, supra note 9.
82. Id.
83. Id.
84. Id.
85. Id.
86. See generally Direct-to-Consumer Prescription Drug Advertising: Hearing Before the
S. Fin. Comm., 107th Cong. 1 (2004) (statement of Dr. David J. Graham, Assistant Director for
Science and Medicine, Food and Drug Administration).
87. Id.
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was an increased risk of heart attack and sudden death.88 Tragically, Merck
did not inform the public of these dangers. 9 In testimony before the Senate
Finance Committee, it was estimated that Vioxx caused between 88,000
and 139,000 cases of heart attacks.90 In 2005, a Texas jury found Merck
liable for $250 million in damages in the first of several lawsuits brought
against Merck for the failure to disclose Vioxx's risks.91
Mechanisms are in place to prevent events such as the Vioxx
disaster.92 Nearly fifty years ago the federal government began to support
the idea that is necessary to disclose accurate information of prescription
drug side effects to ensure the safe use of those drugs.93 These disclosure
requirements become crucial when a drug is marketed directly to the
public.
Today, FDA regulations prohibit prescription drug advertisements
from being false or misleading, and require broadcast advertisements to
contain a brief summary of a drug's side effects.94 Yet stealth celebrity
testimonials flout these requirements. 95 However, the FDA has yet to find
that such activity violates prescription drug regulations. The testimonials
have, in effect, allowed pharmaceutical companies to bypass FDA
requirements which stipulate that advertising messages should include
cautions about prescription drugs and disclose their side effects. 96 Osnat
Benshoshan, an executive at pharmaceutical company Amgen, says, "the
great advantage [of stealth testimonials] over [traditional] advertising... is
there is no fair balance to worry about.,
97
Failing to provide consumers this "fair balance," or basic information
regarding the side effects of a particular prescription drug, while at the
same time relying on the unique influence of a celebrity, exposes the
consumer to the same risks as the Vioxx tragedy. Law exists to protect the
public from the harms associated with stealth celebrity testimonials, yet the
FDA is failing to enforce it.
98
88. Id.
89. Id.
90. Id. at 1-2.
91. Aaron Smith, Jury: Merck Negligent, CNN.COM, Aug. 22, 2005,
http://money.cnn.com/2005/08/19/news/fortune500/vioxx/index.htm.
92. See Sam Peltzman, An Evaluation of Consumer Protection Legislation: The 1962 Drug
Amendments, 81 J. OFPOL. ECON. 1049, 1051 (1973).
93. Id.
94. 21 C.F.R. § 202.1 (2006).
95. Kaikati & Kaikati, supra note 61, at 12.
96. Id.
97. Moynihan, supra note 55, at 113.
98. See Peltzman, supra note 92, at 1051.
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III. THE REGULATION OF PRESCRIPTION DRUG ADVERTISEMENTS
A. Historical Development of Direct-to-Consumer Advertising Regulation
Upton Sinclair, a prolific American author, brought to light the
nauseating conditions of the meatpacking industry and helped lead the way
to the first comprehensive legislation regulating food and drugs.99 The
hazards of the meatpacking industry vividly exposed in his novel, The
Jungle, pushed Congress to enact The Pure Food and Drugs Act of 1906.00
The legislation, also known as the Wiley Act, primarily focused on the
need for informative product labels. The Act stipulated that drugs,
"defined in accordance with the standards of strength, quality, and purity in
the United States Pharmacopoeia and the National Formulary, could not
be sold in any other condition unless the specific variations from the
applicable standards were plainly stated on the label."' ' The Act,
however, did not address drug advertising because labels at the time were
the primary medium for drug promotions. 10 2  While the 1906 Act
represented landmark legislation for its era, it contained significant
deficiencies.
The Wiley Act deems a drug "misbranded" only if its label contained
false statements about its "curative or therapeutic effects."'10 3 However, it
failed to prohibit false claims made off the label, which created a loophole
to allow an unsafe drug to remain on the market. 10 4 In FTC v. Raladam, the
Supreme Court's interpretation of the Federal Trade Commission Act of
1914 widened the loophole. 10 5 Although the Federal Trade Commission
Act gave the Federal Trade Commission (FTC) jurisdiction over
advertising practices, the Court held that the FTC did not have the authority
to regulate deceptive advertisements unless it could prove that such
99. FDA.gov, History of the FDA-The 1906 Food and Drugs Act and its Enforcement,
http://www.fda.gov/oc/history/historyoffda/section .html (last visited Oct. 28, 2007).
100. JOHN P. SWANN, HISTORY OF THE FDA, adapted from A HISTORICAL GUIDE TO THE
U.S. GOVERNMENT (George Kuran ed., 1998), available at
http://www.fda.gov/oc/history/historyoffda/fulltext.html (stating that Sinclair's depiction of the
meat packing industry was the "final precipitating force behind both a meat inspection law and a
comprehensive food and drug law").
101. Id.
102. HARRY A. TOULMIN, JR., A TREATISE ON THE LAW OF FOOD, DRUGS AND COSMETICS
16 (W.H. Anderson Co. 1963) (1942).
103. 21 U.S.C. § 329(a) (amending 21 U.S.C. §§ 1-15 (1934)).
104. See id.
105. See generally FTC v. Raladam, 283 U.S. 643 (1931).
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advertisements injured a competitor. 0 6 These loopholes remained until the
next significant enactment of Food and Drug legislation in 1938.107 Gaps
in the Wiley Act, changes in the pharmaceutical industry and the
aggressive advertising of drugs in newspapers and magazines, necessitated
this new legislation. 108 Sadly, the impetus behind the new legislation was a
"therapeutic disaster" and not foresight or planning.
10 9
In 1937, pharmaceutical company S.E. Massengil marketed a drug to
pediatric patients containing elixir sulfanilamide.' 10 The drug's chemical
makeup was the equivalent of antifreeze, resulting in more than 100 deaths,
the majority of whom were children.' The resulting public outcry led to
the implementation of the Food, Drug, and Cosmetic Act of 1938.112
The Federal Food, Drug, and Cosmetic Act of 1938 (FDCA) repealed
and replaced the Wiley Act.' 13 The new law gave control of cosmetics and
medical devices to the Food and Drug Administration (FDA), requiring the
adequate labeling of drugs for safe use. 1 4  Congress decided to omit
advertising restrictions from the Act and instead conferred jurisdiction over
all drug advertising to the FTC. 1 5 It would take another thirty years before
Congress would grant the FDA authority to regulate prescription drug
advertisements.
16
B. The Modern Regulatory Scheme
1. FDA Gains Power to Regulate Prescription Drug Advertisements
In 1962, the Kefauver-Harris Drug Amendments to the FDCA
transferred regulatory authority over prescription drug advertising from the
FTC to the FDA, by enacting Section 502(n) of the FDCA.11 7  The
106. Harvard Law Review Association, "Corrective Advertising" Orders of the Federal
Trade Commission, 85 HARV. L. REV. 470, 480 (1971).
107. See generally Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as amended at 21
U.S.C. § 301 (2006))
108. TOULMIN, supra note 102, at 16.
109. SWANN, supra note 100.
110. Id.
111. Id.
112. Id.
113. See Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as amended at 21 U.S.C. § 301
(2006)).
114. See 21 U.S.C. § 352(f) (1938).
115. See Wheeler-Lea Act, 52 Stat. 111 (1938).
116. See Drug Amendments of 1962, Pub. L. 87-781, 76 Stat. 780.
117. See 21 U.S.C. § 352(n) (2006).
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amendments were enacted in an effort to protect the public from the
dangers of potentially harmful drugs. s18  The legislation required
manufacturers to provide proof of the effectiveness and safety of their
drugs before approval, and required drug advertisements to disclose
accurate information about side effects and efficacy of treatments., 19
The FDCA in its present form does not actually provide an explicit
definition of what constitutes an advertisement,1 20 but the FDA generally
interprets the term to encompass information (other than labeling) that
promotes a drug product and is sponsored by a manufacturer.1
21
Additionally, FDA regulations provide a list of examples of advertisements
subject to regulation, including "advertisements in published journals,
magazines, other periodicals, and newspapers, and advertisements
broadcast through media such as radio, television, and telephone
,0122communication systems. The manner in which the FDA regulates
advertisements disseminated through these mediums depends largely on
how the FDA characterizes the advertisement.
2. The Types of Advertisements that the FDA Regulates
Although there are numerous mediums through which a
pharmaceutical company may communicate to consumers, the FDA only
recognizes three categories of advertisements and only regulates two of
them. 1 23 The two categories that the FDA regulates are "product-claim"
advertisements and "reminder" advertisements. 24  The third category,
labeled "help-seeking," is free from FDA regulation.
125
Product-claim advertisements include the name of a prescription drug
and its use, or a claim or representation about the safety or efficacy of a
prescription drug. 126  Advertisements containing claims made about
benefits of a particular drug must also disclose risks associated with the
drug.127  The "fair balance" requirement references the disclosure of
118. Peltzman, supra note 92, at 1049-51.
119. See id. at 1051.
120. See 21 U.S.C. § 352(n) (2006).
121. The FDCA defines labeling as any "written, printed, or graphic matter" upon or
accompanying the drug. 21 U.S.C. § 321(k) (2006).
122. 21 C.F.R. § 202.1(k)(1)(1) (2006).
123. 60 Fed. Reg. 42,581, 42,583 (Aug 16 1995).
124. FDA Regulates Prescription Drug Promotion, supra note 6, at 34 (statement of Janet
Woodcock, Director Center for Drug Evaluation and Research, Food and Drug Administration).
125. Id.
126. 60 Fed Reg. 42,581 (Aug. 16, 1995).
127. Id.
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benefits and risks of the drug. 
128
Reminder advertisements, also regulated by the FDA, are
advertisements that contain the product's name and certain descriptive
information, such as correct dosage or price. However, unlike the product
claim advertisements, they do not make any specific claims or
representations about the drug. 2 9 Additionally, the FDA regulations
exempt reminder advertisements from the risk disclosure requirements.'
30
This is because historically, reminder advertisements were directed towards
health care professionals and not the general public.
131
Finally, "Help Seeking" advertisements, unregulated by the FDA,
discuss a disease or condition and advise the audience to see a doctor for
possible treatments.1 32  The FDA does not regulate this type of
advertisement because it does not consider a help-seeking advertisement as
a drug advertisement, because these advertisements do not mention a
specific drug. 1
33
3. The FDA's Statutory Authority to Regulate Advertisements
The FDCA requires manufacturers, packers and distributors who
advertise prescription human and animal drugs, including biological
products for humans, to disclose certain information about the advertised
product's use and risks. 134 Section 502(n) of the FDCA provides the FDA
with the authority to regulate prescription drug advertisements and the
implementing regulations provide specifics about the content of such
advertisements.' 35 It is important to note that neither the statute nor the
implementing regulations prohibit pharmaceutical companies from
advertising directly to consumers in any form.
36
For prescription drugs, the FDCA requires advertisements to give a
brief summary of the drug's "side effects, contraindications and
128. Id.
129. Id.
130. Id.
131. FDA Regulates Prescription Drug Promotion, supra note 6, at 34 (statement of Janet
Woodcock, Director Center for Drug Evaluation and Research, Food and Drug Administration);
see also 60 Fed. Reg. 42,581, 42,583 (Aug. 16, 1995).
132. 60 Fed. Reg. 42,581, 42,582 (Aug. 16, 1995).
133. Id
134. 21 U.S.C. § 352(n) (2006).
135. 21 C.F.R. § 202.1 (2006); see also 21 U.S.C. § 502(n) (2000).
136. FDA Regulates Prescription Drug Promotion, supra note 6, at 35 (statement of Janet
Woodcock, Director Center for Drug Evaluation and Research, Food and Drug Administration).
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effectiveness.' 37 The Act's implementing regulations further specify that
prescription drug advertisements be free from false and misleading
statements and must not omit material facts. 38  These regulations
additionally require advertisements to contain a "fair balance" between
information pertaining to the benefits and risks of a particular drug.'
39
The prescription drug advertising regulations also distinguish between
requirements necessary for print and broadcast advertisements. 14' The
regulations specify that print advertisements must include a brief summary
of risks on the approved package label. 14' Advertisements that are
broadcast through media such as television or radio must disclose a drug's
major side effects in either the audio or visual parts of the presentation.1
42
Sponsors of broadcast advertisements must also present a brief summary or
alternatively make "adequate provision ... for dissemination of the
approved or permitted package labeling in connection with the broadcast
presentation."
'143
In addition to the regulations published in the Federal Register, the
FDA has on occasion issued "Draft Guidance" to clarify its interpretation
of its own regulations. 44  For example, in recognition that the brief
summary requirement is not easily satisfied in a thirty-second television
commercial, FDA regulations allow sponsors of broadcast advertisements
on both television and radio to make "adequate provision" of approved
product labeling rather than providing the entire brief summary in the
advertisement. 45 To clarify how the adequate provision requirement may
be satisfied, the FDA issued a draft guidance in August 1999 entitled
"Guidance for Industry: Consumer-Directed Broadcast Advertisements"
(Guidance). 46  The Guidance details an approach for ensuring that
audiences exposed to prescription drug advertisements on television and
radio have convenient access to the advertised drug's labeling.
147
137. 21 U.S.C. § 352(n) (2006).
138. See 21 C.F.R. § 202.1(e)(5) (2006).
139. Id. § 202.1(e)(5)(ii).
140. See id. § 20 2.1(e)(4 ).
141. Id.
142. See id. § 202.1(e)(1); see also Food and Drug Administration, et al., Guidance for
Industry, Consumer-Directed Broadcast Advertisements (Aug. 1999), available at
http://www.fda.gov/cder/guidance/1804fnl.pdf [hereinafter Guidance for Industry].
143. 21 C.F.R. § 202.1(e)(1) (2006); see also Guidance for Industry, supra note 142.
144. See Guidance for Industry, supra note 142; see also 64 Fed. Reg. 43,197 (Aug. 9,
1999).
145. 21 C.F.R. § 202.1(e)(1) (2006).
146. Guidance for Industry, supra note 142.
147. Id.
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Essentially this informs the pharmaceutical industry that a broadcast
advertisement will not violate the regulations if it complies with the
Guidance. 48 Although the Guidance is technically not legally enforceable,
when a broadcast advertisement conflicts with the Guidance or with the
implementing advertising regulations, the FDA has several tools at its
disposal to ensure compliance with both its regulations and the law.
149
C. The FDA's Failure to Enforce its Own Regulations
The FDA generally cannot require the prescreening of prescription
drug advertisements. 150 Instead, it reviews materials after their
dissemination to the public and then makes a decision as to whether an
enforcement action is necessary.' 5' Within the FDA, the Division of Drug
Marketing, Advertising, and Communications (DDMAC) performs this
task. 152 To ensure compliance with both prescription drug advertising laws
and regulations in general, DDMAC employs a program that monitors
advertisements. 53  Concerned citizens, healthcare practitioners, and
competitor pharmaceutical companies also alert the FDA to questionable
advertisements. 
54
If DDMAC finds that an advertisement violates the law, it issues one
of two letters to the company in violation. 55 The first type of letter, a
Notice of Violation letter (NOV or "untitled letter"), the DDMAC sends for
minor violations. 56 The second type, a warning letter, DDMAC sends for
more serious violations and essentially is an indication that the FDA will
proceed against the manufacturer if it does not initiate corrective action.
57
If an advertiser fails to take corrective action, the FDA has other available
methods of enforcement including seeking an injunction against the
manufacturer or pursuing criminal prosecution.158 To date, the FDA has
not employed any of these more serious enforcement measures for DTC
148. FDA Regulates Prescription Drug Promotion, supra note 6, at 33.
149. Id. at 42.
150. Id. at 36 (statement of Janet Woodcock, Director, Center for Drug Evaluation and
Research, Food and Drug Administration).
151. Id. at 33.
152. Id.; see also FDA.gov, Division of Drug Marketing, Advertising, and Communications,
http://www.fda.gov/cder/ddmac/ (last visited Feb. 23, 2008).
153. FDA Regulates Prescription Drug Promotion, supra note 6, at 40.
154. Id.
155. Id. at 42.
156. Id. at 34.
157. Id.
158. See, e.g., 21 U.S.C. §§ 331-37 (2006).
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advertising violations. In fact, the FDA's overall enforcement of its
advertising regulations has been-as one commentator puts it-rather
"lackadaisical."
159
Between 1998 and 2004 there was an eighty-five percent decline in
enforcement of questionable DTC advertisements on the part of the FDA,
in spite of dramatically increased DTC advertising spending during the
same time-period. 160 Only forty-five warning letters requesting promotion
be stopped immediately were sent during these seven years. In 2002 alone,
there were approximately 6,000 DTC ads.' 6' Lack of enforcement has
become such a problem that Louis Morris, the former head of the FDA's
drug-marketing division was quoted as saying, "FDA enforcement has
waxed and waned.. . I watch TV and say to myself, 'Isn't that illegal?""
162
Even when an enforcement action occurs, the average time between
the initial placement of the drug advertisement and the enforcement action
was 177 days. 163  In a 2002 report, the General Accounting Office
concluded that, "reviews of draft regulatory letters from FDA have taken so
long that misleading advertisements may have completed their broadcast
life cycle before FDA issued the letters."'
' 64
This lack of vigorous enforcement has placed the American consumer
in harm's way for all types of drug advertising. The FDA's "lackadaisical"
enforcement should cause much concern, particularly since the FDA has
never taken enforcement action in response to a celebrity stealth
testimonial.1
65
IV. THE FOOD AND DRUG ADMINISTRATION CAN REGULATE STEALTH
CELEBRITY TESTIMONIALS UNDER CURRENT REGULATIONS
Although the Food and Drug Administration (FDA) has failed to
regulate stealth celebrity testimonials of prescription drugs, the FDA does
159. Impact of Direct-to-Consumer Drug Advertising, supra note 50 (statement of Peter
Lurie, Deputy Director of Public Citizens Health Research Group).
160. See Warning Letters and Untitled Letters to Pharmaceutical Companies 1998-2004,
http://www.fda.gov/cder/warn/ (last visited Feb. 8, 2008).
161. See id.; see also FDA Regulates Prescription Drug Promotion, supra note 6, at 41.
162. Julie Schmidt, FDA Races to Keep up with Drug Ads That Go Too Far, USA TODAY,
May 30, 2005, available at http://www.usatoday.com/money/industries/health/drugs/2005-05-30-
drug-ads-usat x.htm?POE=MONISVA.
163. Impact of Direct-to-Consumer Drug Advertising, supra note 50, at 93.
164. U.S. GENERAL ACCOUNTING OFFICE, supra note 32, at 23.
165. See Warning Letters and Untitled Letters to Pharmaceutical Companies 1998-2004,
supra note 160.
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have the authority to do so, 66 and the testimonials are characteristically
similar to the advertisements that they have regulated in the past. 167 A
stealth testimonial is essentially a more subtle form of a traditional
advertisement. Therefore, just as the FDA regulates traditional
advertisements, it should also regulate stealth testimonials. Not doing so
leaves the public at risk. For the following reasons, the FDA should
regulate stealth celebrity testimonials.
A. Celebrity Stealth Testimonials Constitute Advertising under the
Federal Food, Drug, and Cosmetic Act of 1938
The Federal Food, Drug, and Cosmetic Act (FDCA) does not define
what constitutes "advertising."1 68 The only guidance in the area are FDA
regulations that illustrate the various mediums through which
advertisements are subject to regulation. 169  However, the list is not
exhaustive. In the past, methods of advertising outside of those enumerated
in the regulations have been subject to FDA supervision. 70 For example,
in addition to those mediums listed, the FDA regulates advertising
conducted through sales representatives, computer programs, fax machines,
and online message boards.' 7' This demonstrates the FDA's willingness to
expansively interpret its regulatory authority over the various channels
through which businesses disseminate their advertisements. The FDA
should apply a similar approach to regulating newly emerging forms of
advertising not yet listed in FDA regulations.
Black's Law Dictionary defines advertising as "the action of drawing
166. See 21 U.S.C. §§ 331(a)-(b), 352(a), (f), (n) (2006) (statutory authority for prohibition
against misbranding and requirement of fair balance in advertising); see also 21 C.F.R. § 202.1
(2006) (FDA interpretive regulations).
167. See Letter from Thomas W. Abrams, Director, Division of Drug Marketing,
Advertising and Communications, FDA, to Raymond V. Gilmartin, President and CEO, Merck &
Co., Inc. (Sept. 17, 2001), available at http://www.fda.gov/cder/warn/wam200l.htm (finding
Merck had engaged in a promotional campaign that minimized the potential risks and
misrepresented the safety profile for Vioxx.); see also Letter from Barbara S. Chong, Regulatory
Review Officer, Division of Drug Marketing, Advertising and Communications, FDA, to Susan
P. Rinne, Vice President, Regulatory Affairs, Alza Corp. (Jul. 12, 2001), available at
http://www.fda.gov/cder/wam/wam2001/10196.pdf (finding Alva Corp. DTC Advertisements for
Ditrospan XL were false and misleading by suggesting the drug was more effective than it was
and failing to disclose important facts about its limitations).
168. See generally Federal Food, Drug, and Cosmetic Act of 1938, 21 U.S.C. §§ 331, 352
(2000).
169. See 21 C.F.R. § 202.1(k)(1)(1) (2006).
170. SWARBRICK & BROLIN, ENCYCLOPEDIA OF PHARMACEUTICAL TECHNOLOGY 48
(Michael Drekker, Inc. Informa Health Care 2d ed. 2002) (1992).
171. Id.
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the public's attention to something to promote its sale."' 7 2 Similarly, in his
book Promotion and Integrated Marketing Communications, Richard
Semenik defines advertisements as a "specific message an organization has
placed to persuade an audience."'' 73 These definitions, combined with the
FDA's interpretation of its powers to regulate advertising, are sufficiently
broad for the FDA to assert authority over stealth celebrity testimonials.
When a pharmaceutical company compensates a celebrity to appear
on a talk show, as was the case in Lauren Bacall's appearance on The
Today Show, it does so in an attempt to persuade the consumer.174 As the
court in Lugosi v. Universal Pictures explains, the company is
commercially using a celebrity's persona in a manner "intended to increase
the value or sales of the product by fusing the celebrity's identity with the
product and thereby siphoning some of the publicity value... in the
celebrity's persona into the product."'' 75  Bacall's compensation for
mentioning the drug Visodyne on The Today Show, and Kathleen Turner's
remuneration for directing Good Morning America viewers to a website
operated by Wyeth, both constitute a form of advertising. These examples
of stealth celebrity testimonials are not only advertisements as defined by
the FDCA, but are also of the character that the FDA traditionally
regulates. 176
B. Celebrity Stealth Testimonials are of the Type ofAds that the FDA
Traditionally Regulates
As previously mentioned, the FDA regulates two classifications of
advertisements, "Reminder Ads" and "Product Claim Ads.' 77  Both
categories involve the identification of specific drugs, but the product claim
category deals with those ads that contain assertions of a drug's benefits,
safety, and effectiveness. 178  This latter category is arguably more
dangerous to the consumer due to the potential for the advertisement to
include false or misleading statements. The FDA should classify many
stealth celebrity testimonials as product claim advertisements.
A stealth celebrity testimonial constitutes a product claim
172. BLACK'S LAW DICTIONARY 55 (7th. ed. 1999).
173. RICHARD SEMENIK, PROMOTION & INTEGRATED MARKETING COMMUNICATIONS 555
(South-Western 2002).
174. Petersen, supra note 9.
175. Lugosi v. Universal Pictures, 623 P.2d 425, 438 (Cal. 1979).
176. FDA Regulates Prescription Drug Promotion, supra note 6, at 34 (statement of Janet
Woodcock, Director Center for Drug Evaluation and Research, Food and Drug Administration).
177. Id.
178. Id.
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advertisement when a pharmaceutical company provides financial
remuneration to a celebrity who has appeared on television and that
celebrity has made assertions in regards to a specific drug's benefits, safety,
or effectiveness. Lauren Bacall's appearance on The Today Show to
encourage viewers to see their doctors about macular degeneration, during
which she mentioned Novartis' prescription drug Visodyne, was
unmistakably a claim about the use of the drug.179 Likewise, by featuring
the drug Copaxone on his show and stating it that was what has "kept him
running," Montel Williams was making an assertion about the effectiveness
of the drug. 80  The specific claims made during these testimonials, and
others like them, should subject these advertisements to FDA regulations
such as those requiring specific disclosures of the benefits and risks of a
particular drug.
The FDA requires prescription advertisements to include a "true
statement of information in brief summary relating to side effects,
contradictions and effectiveness" of the drug advertised.181 A manufacturer
fails to meet this true statement requirement if an advertisement is "false or
misleading, does not present fair balance between side effects and
contraindications information or effectiveness information, or fails to
reveal material facts."' 182  The FDA realizes that requiring a complete
listing of side effects and other balance information is impracticable for
broadcast advertising. Instead, the FDA requires such advertising only to
include statements concerning major risks of the drug advertised, "provided
that the manufacturer makes adequate provision for the dissemination of
the approved package labeling."' 83 In determining whether a violation has
occurred the regulations call for the FDA to go beyond supervising the
"veracity in advertising statements to examine how the information is
presented."'' 84  Information regarding side effects must be presented
prominently and regulations require several factors to be considered in
determining whether an advertisement has run afoul of this requirement.'
85
179. Id.
180. Petersen, supra note 9.
181. 21 C.F.R. § 202.1(e) (2006).
182. RICHARD R. ABOOD, PHARMACY PRACTICE AND THE LAW 76-77 (Jones and Bartlett
Publishers 2005).
183. Id. at 77.
184. Pa. Emps. Benefit Trust Fund v. Zeneca, Inc., 499 F.3d 239, 245 n.8 (3d Cir. 2007).
185. 21 C.F.R. § 202.1(e)(7)(viii) (2006) (stating some of the factors are whether the
advertisement fails to present information relating to side effects and contraindications with a
prominence and readability reasonably comparable with the presentation of information relating
to effectiveness of the drug ... and whether the advertisement fails to provide sufficient emphasis
for the information relating to side effects and contraindications, when such information is
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If an advertisement fails to meet these standards then it is deemed false and
misleading. 186
The incidents involving Mr. Williams and Ms. Bacall demonstrate
how stealth celebrity ads will usually fail to meet the FDA's standards.
While both celebrities made claims about the benefits of a particular drug,
neither sought to balance these claims with information regarding the side
effects or effectiveness of these drugs. Additionally, both incidents failed
to make adequate provision for the dissemination of the package labeling of
the drugs mentioned. Applying the FDA's own standards, these
testimonials are misleading and false. They fail to meet FDA regulations
regarding presentation and more importantly ignore the FDA's fair balance
requirement. Yet the FDA has taken no action. Its failure to enforce its
regulations on celebrity stealth testimonials has exposed the public to
unnecessary danger and runs counter to congressional intent in enacting the
FDCA.
C. The Congressional Intent of Enacting the FDCA
The FDA's failure to regulate celebrity stealth testimonials thwarts
Congress' intent in enacting the FDCA. Congress enacted the FDCA to
protect the public's health and welfare. 187 Because the FDCA sought to
protect consumers against fraud, the Supreme Court has construed it
liberally. 188  The Court in United States v. Dotterweich noted that
"[b]alancing relative hardships, Congress has preferred to place it upon
those who have at least the opportunity of informing themselves of the
existence of conditions imposed for the protection of consumers before
sharing in illicit commerce, rather than to throw the -hazard on the innocent
public who are wholly helpless."'' 89 Accordingly, the Court has interpreted
the FDCA in favor of protecting consumers even though this may result in
hardships for the product manufacturers or advertisers.' 90
In enacting the FDCA, Congress sought to protect the consumer by
"ensuring that drugs sold in the marketplace are safe, effective, and not
contained in a distinct part of an advertisement, because of repetition or other emphasis in that
part of the advertisement of claims for effectiveness or safety of the drug.).
186. Id. § 202.1(e)(7)(viii).
187. See C.C. Co. v. United States, 147 F.2d 820, 824 (5th Cir. 1944); see also United
States v. Sullivan, 332 U.S. 689, 696 (1948) (stating "the Act as a whole was designed primarily
to protect consumers from dangerous products.").
188. United States v. Kordel 164 F.2d 913 (7th Cir. 1947), aff'd 335 U.S. 345 (1948); see
also United States v. Lee 131 F.2d 464, 466 (7th Cir. 1942).
189. United States v. Dotterweich, 320 U.S. 277, 285 (1943).
190. Id.
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misbranded."' 91  To effectuate these goals Congress included the fair
balance requirements. Under the Act, an advertisement is "false, lacking in
fair balance, or otherwise misleading if it [f]ails to present information
relating to side effects and contraindications."' 92  Unbalanced celebrity
prescription drug testimonials clearly contravene the Act. This is exactly
what Congress sought to prevent with the enactment of the FDCA.
Celebrity stealth testimonials place consumers at a greater risk of
harm than more traditional forms of advertising. Consumers see celebrities
as trustworthy and knowledgeable spokespersons for the products they
endorse. 193 Celebrity advertisements offer the pharmaceutical companies a
"premium" because they are more effective at reaching consumers than
general advertising, thus generating higher consumer awareness and
retention levels. 194  "When a celebrity talks about something everyone
stands up and takes notice," states Dr. Jonathan Sackier, founder of the
company Spotlight Health, which develops celebrity medical education
campaigns for health care concerns. 9 5 Indeed, a celebrity testimonial of a
particular prescription drug creates what one industry insider has called an
"intangible sort of magic."'
196
Celebrity drug testimonials are especially dangerous because they
usually fail to disclose the adverse effects of prescription drugs. Because
stealth testimonials "fly under the radar, tucked away in places where
consumers expect non-commercial reality,"' 97 a testimonial that does not
address a drug's major side effects endangers consumers who are less
likely to appreciate that the testimonial is a paid advertisement. In light of
the FDCA's consumer protection and anti-fraud goals, these highly
surreptitious testimonials contravene Congress' expressed intent. Congress
has not yet responded to this problem, but if the FDA continues to neglect
its statutory duties, they may have to enact further legislation.
191. Mut. Pharm. Co. v. Ivax Pharms., Inc., 459 F. Supp. 2d 925, 933 (2006).
192. Pa. Emps. Benefit Trust Fund v. Zeneca, Inc., 499 F.3d 239, 245 n.8 (3d Cir. 2007)
193. Moynihan, supra note 55, at 103.
194. See generally Celebrities in Advertising: What are they likely or not likely to Do?:
Public Hearing on Direct to Consumer Promotion of Medical Products Before the Food and
Drug Administration 4 (2005) (presentation of Abhilasha Metha, Director of Research, Robinson
& Gallup, Inc.).
195. Petersen, supra note 9.
196. Moynihan, supra note 55.
197. Michael McCarthy, Ads Show up in Unexpected Places, USA TODAY, Mar. 23, 2001,
at lB (speaking generally about Stealth Advertising).
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D. Recent Amendments to the FDCA Fail to Address Stealth Celebrity
Testimonials
On September 27, 2007, Congress reauthorized the FDCA with the
Food and Drug Administration Amendments Act of 2007.'9' The
amendments give the FDA the authority to require post-approval labeling
changes of prescription drugs, collect larger fees to fund oversight
operations of Direct-to-Consumer (DTC) advertisements and impose new
civil penalties for violations of the FDCA.199 Some contend that the
reauthorization is "the most comprehensive overhaul of food and drug law
since 1997. "200 While this may be true, these amendments fail to
meaningfully address DTC advertising.2 1 Congress' failure is a victory for
the pharmaceutical advertising industry.
202
Speaking about the reauthorization, Mike Rutstein, Executive Vice
President of Consumer Health Care at Interpublic Group stated, "[t]he
upside is the fact that it's not changing significantly, because it could have
been an ugly picture. '203 Originally, the House and Senate bills contained
provisions that, if approved, would have required a moratorium on DTC
advertising for new drugs, 20 4 pre-clearance of ads by the FDA, and new
mandatory warning requirements for advertising. 20 5  However, the
combined efforts of the drug and advertising industries eviscerated any
language in the reauthorizing legislation that would have significantly
changed drug advertising regulation.20 6 Accordingly, it is not surprising
that no provision of the new legislation specifically addresses celebrity
stealth testimonials, and very little in the law substantially affects DTC
advertising.20 7
198. Food and Drug Administration Amendments Act of 2007, Pub.L. 110-85, 121 Stat.
823.
199. Memorandum from Reed Smith LLP, supra note 43.
200. Id.
201. See, e.g., Anna W. Matthews & Stephanie King, Media Industry Helped Drug Firms
Fight Ad Restraints, WALL ST. J., Sept. 21, 2007, at B1.
202. Press Release, American Association of National Advertisers, Inc., Ad, Media Groups
Help Derail Drug Ad Restrictions-Commercial Alert, (Sept. 21, 2007) available at
http://www.ana.net/news/content/835.
203. Matthews & King, supra note 202.
204. Enhancing Drug Safety and Innovation Act of 2007, H.R. 1561, 110th Cong. § 101(H)
(1st Sess. 2007).
205. Matthews & King, supra note 202.
206. Id.
207. See Food and Drug Administration Amendments Act of 2007, Pub. L. 110-85, 121
Stat. 823 (codified in scattered sections of 21 U.S.C. and 42 U.S.C.).
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Congressional inaction regarding celebrity stealth testimonials
20 8
combined with the FDA's dereliction of its law enforcement duties
20 9
leaves consumers in precarious positions. As it stands now, stealth
celebrity prescription drug testimonials are too dangerous for the status quo
to continue.
V. A PRAGMATIC SOLUTION
Not only do celebrity stealth prescription drug testimonials violate the
Federal Food, Drug and Cosmetics Act of 1938 (FDCA),21° they also place
the consumer's health at risk.211  Even though the current law provides a
framework that is sufficient to regulate these testimonials, 21 2 the Food and
Drug Administration (FDA) does not adequately enforce it.
213
The FDA could take a more proactive approach in policing stealth
celebrity prescription drug testimonials. First, the FDA could apply the
current regulatory framework and completely ban celebrity testimonials of
prescription drugs.214 This option may eliminate the potential dangers
associated with stealth testimonials, 215  but it also obliterates their
benefits. 1 6 Among these benefits is improved consumer awareness of
certain ailments and their treatments, which can induce consumers to seek
information from physicians about certain prescription drugs. 217 Moreover,
this option raises serious First Amendment issues.2 18 The negative aspects
208. Id.
209. See, e.g., Impact of Direct-to-Consumer Drug Advertising, supra note 50, at 90-99
(statement of Peter Lurie, Deputy Director of Public Citizens Health Research Group).
210. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 331, 352 (2000).
211. Petersen, supra note 9.
212. See FDCA 21 §§ U.S.C. 331(a),(b), 352(a),(f),(n) (2006) (statutory authority for
prohibition against misbranding and requirement of fair balance in advertising); see also 21
C.F.R. §§ 202.1 et. seq. (FDA implementing regulations).
213. Impact of Direct-to-Consumer Drug Advertising, supra note 50, at 90-99 (statement of
Peter Lurie, Deputy Director of Public Citizens Health Research Group).
214. Food and Drug Administration Amendments Act of 2007, Pub. L. 110-85, 121 Stat.
823 (codified in scattered sections of 21 U.S.C. and 42 U.S.C.).
215. See, e.g., Petersen, supra note 9.
216. See Alison Masson & Paul H. Rubin, Matching Prescription Drugs and Consumers:
The Benefits of Direct Advertising, 313 NEW. ENG. J. MED. 513, 513-15 (2002) (noting that DTC
advertising results in a more informed consumer.).
217. John E. Calfee, Public Policy Issues in Direct to Consumer Advertising of Prescription
Drugs, 19 J.L. & ECON. 174, 225 (2002).
218. See Bd. of Trs. v. Fox, 492 U.S. 469, 477 (1989) (discussing how although commercial
speech receives a lesser degree of protection than traditional First Amendment issues, in recent
years there has been a shift towards greater protection for commercial speech); see also 44 Liquor
Mart v. Rhode Island, 517 U.S. 484, 516 (1996) (invalidating unjustifiably broad statutes curbing
speech); Cincinnati v. Discovery Network, 507 U.S. 410, 429-31 (1993) (striking down a city
126 LOYOLA OF LOS ANGELES ENTERTAINMENT LAW REVIEW [Vol. 28:101
associated with a complete proscription of all celebrity testimonials
undermine the viability of this options' implementation.
Alternatively, the FDA could issue a draft guidance to the
pharmaceutical industry asserting that celebrity stealth testimonials are
subject to its Direct-to-Consumer advertisement regulations. This guidance
would stipulate that the general restrictions governing traditional broadcast
television advertisements apply where a celebrity receives compensation to
promote a particular prescription drug in a setting that is not clearly
commercial in nature, such as a talk show. 21 9 This would require any paid
celebrity testimonial stating the benefits of a prescription drug to: (1)
disclose the drugs' sponsor; (2) include a brief statement summarizing the
major side effects of the drug; and (3) provide adequate provision for the
consumer to gain access to further details about the drug.2 ° Satisfying the
adequate provision requirement would also require advertisers to mention a
toll-free telephone number, website, or other comparable form of
information dissemination where consumers could access more details
about the promoted drug.221
This option would put the industry on notice as to what the FDA
would consider proscribed behavior, and would remove the stealth aspects
of celebrity testimonials without raising the same First Amendment
concerns as a complete prohibition. In addition, this option would
minimize the pharmaceutical industry's burden because the proposed
standard is the same one that applies to traditional broadcast television
commercials.
Thus, if this guidance had been in place when Lauren Bacall appeared
on NBC's The Today Show to promote Visudyne or when Montel Williams
highlighted Copaxone, there would have been specific disclosures alerting
unassuming consumers to the commercial nature of the testimonials. This
would have given consumers a better way of informing themselves about
the risks of the promoted drugs. Under this approach, celebrity
testimonials would no longer contain the deceptive element that one critic
ordinance banning news racks of advertising brochures for aesthetic and safety reasons).
219. The guidance suggested would address only those incidents where celebrities receive
compensation for promoting a prescription drug. A broader application of FDA regulations to
non-compensated celebrity testimonials seems beyond the authority conferred to the FDA under
the FDCA. Additionally, the feasibility of enforcing a broader application combined with certain
speech infringement issues that would arise from its enforcement make such an approach not
viable.
220. Food and Drug Administration, Guidance for Industry, Consumer-Directed Broadcast
Advertisements (Aug. 1999), available at http://www.fda.gov/cder/guidance/1804fnl.htm.
221. Id.
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claims differentiates stealth marketing from traditional advertising.222
Therefore, a draft guidance that specifically covers celebrity stealth
testimonials is a simple solution to a problem that jeopardizes the public's
health and safety. However, given Congress' recent failure to address the
issue and the FDA's historical apathy towards enforcing its own
regulations, the likelihood of governmental action on the issue is
questionable. 3
In the absence of FDA action or new legislation on the matter, the
only way to solve this problem is for celebrities to refrain from giving
stealth drug testimonials. It is in celebrities' best interest to avoid
surreptitiously promoting prescription drugs because stealth testimonials
may cause a consumer backlash. "Instead of delighting or surprising
consumers, the surreptitious campaign could negatively impact the brand
because consumers feel they have been duped., 224 A recent press release
from Bob Brody, a media specialist at Ogilvy, discusses this possible
backlash and suggests that media outlets are keenly aware of the dangers of
celebrity testimonials.225 The press release states that The Today Show,
which Mr. Brody calls the "Holy Grail" of celebrity health campaigns, has
severely restricted any such promotions on its program and the Associated
Press will not lend its name to any celebrity promotion of a pharmaceutical
that it deems "unduly commercial. 226
However, the effectiveness of these measures is potentially limited.
Markets generally have mixed reactions to questionable advertising and
some media outlets "still love celebrity health campaigns. 227 In addition,
there are inherent deficiencies in relying solely on consumer backlash to
defend against stealth celebrity testimonials. For example, any lag time
between the consumer backlash and corrective action by the prescription
drug industry represents a time period of potential harm to consumers.
Therefore, there is no perfect solution to these public health and safety
dangers.
222. Undercover Marketing Uncovered: Hidden Cameras Capture Salespeople Secretly
Pitching Products, CBSNEwS, July 25, 2004, available at
http://www.cbsnews.com/stories/2003/10/23/60minutes/main579657.shtml.
223. See Matthews & King, supra note 202; see also Impact of Direct-to-Consumer Drug
Advertising, supra note 50, at 90 (statement of Peter Lurie, Deputy Director of Public Citizens
Health Research Group).
224. Kaikati & Kaikati, supra note 61, at 18.
225. Bob Brody, Ogilvy Public Relations Worldwide, Celebrity Health Campaign: The
Next Generation, at 1, available at http://www.ogilvypr.com/pdf/celebrity-health-campaigns.pdf.
226. Id.
227. Id.
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VI. CONCLUSION
The fragmentation of the media has impaired the effectiveness of
traditional forms of advertising, forcing those who wish to promote their
brands to develop novel methods to reach the consumer. One means of
doing so has been the stealth advertisement. The stealth advertisement,
although efficient in cutting through the clutter, poses unique dangers to the
consumer, especially in the context of prescription drugs. These dangers
heighten when pharmaceutical companies employ celebrities to promote
their products. Yet this practice remains unregulated and, in the absence of
regulation, the marketplace has provided an incomplete solution to the
problem. To ensure consumer safety, government action is necessary. The
Food and Drug Administration must begin to regulate stealth celebrity
testimonials of prescription drugs.
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